CD274 and urothelial carcinoma: This antibody has been validated and approved for use in the complementary assay kit, Ventana PD-L1 (SP142), to detect PD-L1 expression and guide clinical therapy with atezolizumab for advanced urothelial carcinoma and non-small cell lung cancer (NSCLC) [26–29].